Mizuho Initiates Coverage On Eikon Therapeutics with Outperform Rating, Announces Price Target of $26
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Outperform rating and announces Price Target of $26.
Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Outperform rating and announces Price Target of $26.